Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013

GlobalData
February 28, 2014
157 Pages - SKU: GBDT5219277


Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q4 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


Additional Information

Deal Values in Pharmaceutical & Healthcare Industry Increased in Q4 2013

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q4 2013. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma deals database and through primary and secondary research.

Deal Values Of M&A’s Increased In Q4 2013

Merger and acquisition (M&A) deals, including asset purchases, recorded a decrease in the number of deals and an increase in deal values in Q4 2013 with 336 deals worth $41.8 billion, compared to 382 deals worth $18.9 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals and their values decreased in Q4 2013, compared to 399 deals worth $55.4 billion in Q3 2013.

The central nervous system therapeutics markets recorded the highest number of deals in Q4 2013 and stood at the top in deal activity. The market recorded 37 deals worth $9 billion in Q4 2013.

McKesson Corporation, a healthcare services and IT company, through its wholly-owned indirect subsidiary Dragonfly GmbH & Co KgaA, announcing to acquire Celesio AG, a provider of logistics and services in the pharmaceutical and healthcare sector, for a purchase consideration of €6.2 billion ($8.49 billion) or €23.5 ($32.21) per share and AstraZeneca PLC, a biopharmaceutical company, announcing to acquire the remaining 50% stake in a diabetes joint venture (JV) from Bristol-Myers Squibb Company (BMS), a pharmaceutical company, for a purchase consideration of $4.3 billion, were some of the high value deals reported in Q4 2013.

Partnership Deals Decreased In Q4 2013

Partnership deals reported a decrease in the number of deals and an increase in deal values in Q4 2013 with 196 deals worth $6.7 billion, as compared to 230 deals worth $4.3 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2013, when compared to 208 deals worth $3.5 billion in Q3 2013.

In Q4 2013, 120 were co-development deals, 36 were co-marketing deals, 28 were joint venture deals and 12 were related to other category. Much of the partnership deals were reported in oncology therapeutics markets in Q4 2013. The market reported 39 deals worth $3.5 billion in Q4 2013.

Pharmaceutical and healthcare companies entered into 124 partnerships for Marketed stage products, which accounted for 38% of the deals from Q4 2012 to Q4 2013. Products in Discovery phase stood second with 90 deals, which accounted for 27% of the deals.

Licensing Deals Repoted A Decrease In Number In Q4 2013

Licensing agreements recorded a marginal decrease in the number of deals and an increase in deal values in Q4 2013 with 135 deals worth $5.7 billion, as compared to 136 deals worth $4.8 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2013, when compared with 158 deals worth $4.2 billion in Q3 2013.

Licensing agreements recorded a decrease in the receipt of upfront payments and an increase in milestone payments in Q4 2013. The segment reported $261.3m and $4.3 billion as upfront and milestone payments in Q4 2013, compared to $661.3m and $3.6 billion, respectively, in Q4 2012. On a quarter-on-quarter basis, the receipt of upfront payments reported a decrease and milestone payments increased in Q4 2013, compared to $644.1m and $2.9 billion, respectively, in Q3 2013.

In licensing by phase, products in Marketed phase recorded 104 deals, which accounted for 32% of the total deals between Q4 2012 and Q4 2013. In second place, products in Phase II accounted for 24% of the deals.

Venture Capital Investments Remained Same In Q4 2013

The pharmaceutical and healthcare industry recorded a decrease in the number of venture capital (VC) deals and their values remained same with 237 deals worth $2.5 billion in Q4 2013, as compared to 327 deals worth $2.5 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2013, when compared to 259 deals worth $1.8 billion in Q3 2013. Orbimed Advisors, LLC and Polaris Venture Partners topped the list of venture financing firms by participating in 16 transactions each worth $414.8m and $392.9m, respectively, in the last five quarters (Q4 2012 – Q4 2013).

Deals in start-up stage constituted 54% of the total deals in Q4 2013. In second place, growth/expansion stage financing recorded 80 deals, accounting for 34% of the total deals.

North America Reported An Increase In Values In Q4 2013

North America recorded a decrease in the number of deals and an increase in deal values in Q4 2013. The region registered 844 deals worth $67.3 billion in Q4 2013, compared to 948 deals worth $58.1 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2013, when compared to 912 deals worth $65 billion in Q3 2013.

Europe recorded a decrease in the number of deals and an increase in deal values in Q4 2013 with 306 deals worth $25.7 billion, as compared to 396 deals worth $20 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2013, when compared to 345 deals worth $18.5 billion in Q3 2013.

Asia Pacific recorded a decrease in the number of deals and deal values in Q4 2013. The region reported 247 deals worth $11.2 billion in Q4 2013, as compared to 311 deals worth $17.1 billion in Q4 2012. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q4 2013, when compared to 351 deals worth $9.8 billion in Q3 2013.

Country

Global

Sector

Pharmaceuticals and Healthcare

More Pharmaceuticals Company reports by GlobalData

Array BioPharma Inc. (ARRY) - Financial and Strategic SWOT Analysis Review by GlobalData
Array BioPharma Inc. (ARRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The ...
Cooper Energy Limited, Company Intelligence Report by GlobalData
Cooper Energy Limited, Company Intelligence ReportSummaryCooper Energy Limited (Cooper Energy) is an independent upstream energy company engaged in the Exploration and Production (E&P) of oil ...
Celesio AG (CLS1) - Financial and Strategic SWOT Analysis Review by GlobalData
Celesio AG (CLS1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile ...
Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review by GlobalData
Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 1,500  
    Site License  USD 3,000  
    Global Site License  USD 4,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!